Aurinia will explore possible sale, following push by shareholder

Drew Armstrong

Executive Editor

Kyle LaHucik

Senior Reporter

Aurinia Pharmaceuticals said it will start exploring strategic alternatives, including a potential sale. The announcement follows calls by one of its major shareholders, MKT Capital …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aurinia will explore possible sale, following push by shareholder

Drew Armstrong

Executive Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Au­rinia will ex­plore pos­si­ble sale, fol­low­ing push by share­hold­er

Executive Editor

Senior Reporter

Sign up to read this article for free.

Aurinia will explore possible sale, following push by shareholder